메뉴 건너뛰기




Volumn 42, Issue 1, 2015, Pages 87-93

Antihyperglycemic effect of ipragliflozin, a sodium-glucose co-transporter 2 inhibitor, in combination with oral antidiabetic drugs in mice

Author keywords

Antidiabetic drugs; Blood glucose; Ipragliflozin; Sodium glucose transporter 2; Type 2 diabetes mellitus

Indexed keywords

GLIBENCLAMIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; IPRAGLIFLOZIN; METFORMIN; NATEGLINIDE; PIOGLITAZONE; SITAGLIPTIN; VOGLIBOSE; ANTIDIABETIC AGENT; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2; THIOPHENE DERIVATIVE;

EID: 84919609106     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12317     Document Type: Article
Times cited : (9)

References (31)
  • 1
    • 73349099345 scopus 로고    scopus 로고
    • Insulin therapy and quality of life. A review
    • Pouwer F, Hermanns N. Insulin therapy and quality of life. A review. Diabet. Metab. Res. Rev. 2009; 25(Suppl. 1): S4-10.
    • (2009) Diabet. Metab. Res. Rev. , vol.25 , pp. S4-10
    • Pouwer, F.1    Hermanns, N.2
  • 2
    • 0029147687 scopus 로고
    • Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study
    • Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabet. Res. Clin. Prac. 1995; 28: 103-17.
    • (1995) Diabet. Res. Clin. Prac. , vol.28 , pp. 103-117
    • Ohkubo, Y.1    Kishikawa, H.2    Araki, E.3
  • 3
    • 0032511583 scopus 로고    scopus 로고
    • Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33
    • UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
    • (1998) Lancet , vol.352 , pp. 837-853
  • 4
    • 0032742992 scopus 로고    scopus 로고
    • The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus
    • Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-94.
    • (1999) J Clin Invest , vol.104 , pp. 787-794
    • Weyer, C.1    Bogardus, C.2    Mott, D.M.3    Pratley, R.E.4
  • 5
    • 0035340067 scopus 로고    scopus 로고
    • Oral agents in the management of type 2 diabetes mellitus
    • Luna B, Feinglos M. Oral agents in the management of type 2 diabetes mellitus. Am. Fam. Physician 2001; 63: 1747-56.
    • (2001) Am. Fam. Physician , vol.63 , pp. 1747-1756
    • Luna, B.1    Feinglos, M.2
  • 6
    • 84873029199 scopus 로고    scopus 로고
    • AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: A summary of the key findings
    • Bennett WL, Balfe LM, Faysal JM. AHRQ's comparative effectiveness research on oral medications for type 2 diabetes: A summary of the key findings. J. Manag. Care Pharm. 2012; 1(Suppl. A): s3-20.
    • (2012) J. Manag. Care Pharm. , vol.1 , pp. s3-20
    • Bennett, W.L.1    Balfe, L.M.2    Faysal, J.M.3
  • 7
    • 0028874605 scopus 로고
    • The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995; 18: 1510-18.
    • (1995) Diabetes Care , vol.18 , pp. 1510-1518
  • 8
    • 60449089649 scopus 로고    scopus 로고
    • Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy
    • Nathan DM, Holman RR, Buse JB et al. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care 2009; 32: 193-203.
    • (2009) Diabetes Care , vol.32 , pp. 193-203
    • Nathan, D.M.1    Holman, R.R.2    Buse, J.B.3
  • 9
    • 0032983666 scopus 로고    scopus 로고
    • Glycemic control with diet, sulfonylurea, metformin, or insulin in Patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49)
    • Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in Patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-12.
    • (1999) JAMA , vol.281 , pp. 2005-2012
    • Turner, R.C.1    Cull, C.A.2    Frighi, V.3    Holman, R.R.4
  • 10
    • 0347133334 scopus 로고    scopus 로고
    • Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes
    • Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-42.
    • (2004) JAMA , vol.291 , pp. 335-342
    • Saydah, S.H.1    Fradkin, J.2    Cowie, C.C.3
  • 11
    • 78651406659 scopus 로고    scopus 로고
    • SGLT2 mediates glucose reabsorption in the early proximal tubule
    • Vallon V, Platt KA, Cunard R et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J. Am. Soc. Nephrol. 2011; 22: 104-12.
    • (2011) J. Am. Soc. Nephrol. , vol.22 , pp. 104-112
    • Vallon, V.1    Platt, K.A.2    Cunard, R.3
  • 12
    • 34547449243 scopus 로고    scopus 로고
    • Regulatory mechanisms of Na+/glucose cotransporters in renal proximal tubule cells
    • Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of Na+/glucose cotransporters in renal proximal tubule cells. Kidney Int. 2007; 72: s27-35.
    • (2007) Kidney Int. , vol.72 , pp. s27-s35
    • Lee, Y.J.1    Lee, Y.J.2    Han, H.J.3
  • 13
    • 48249146624 scopus 로고    scopus 로고
    • Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
    • Han S, Hagan DL, Taylor JR et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes 2008; 57: 1723-9.
    • (2008) Diabetes , vol.57 , pp. 1723-1729
    • Han, S.1    Hagan, D.L.2    Taylor, J.R.3
  • 14
    • 0032850016 scopus 로고    scopus 로고
    • T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes
    • Oku A, Ueta K, Arakawa K et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999; 48: 1794-800.
    • (1999) Diabetes , vol.48 , pp. 1794-1800
    • Oku, A.1    Ueta, K.2    Arakawa, K.3
  • 15
    • 77953857048 scopus 로고    scopus 로고
    • Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial
    • Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 375: 2223-33.
    • (2010) Lancet , vol.375 , pp. 2223-2233
    • Bailey, C.J.1    Gross, J.L.2    Pieters, A.3    Bastien, A.4    List, J.F.5
  • 16
    • 84862875221 scopus 로고    scopus 로고
    • Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy
    • Rosenstock J, Salsali A, Vico M, List JF, Wei L. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA1c, body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012; 35: 1473-8.
    • (2012) Diabetes Care , vol.35 , pp. 1473-1478
    • Rosenstock, J.1    Salsali, A.2    Vico, M.3    List, J.F.4    Wei, L.5
  • 17
    • 84861781220 scopus 로고    scopus 로고
    • Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes
    • Rosenstock J, Usiskin K, Aggarwal N et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012; 35: 1232-8.
    • (2012) Diabetes Care , vol.35 , pp. 1232-1238
    • Rosenstock, J.1    Usiskin, K.2    Aggarwal, N.3
  • 18
    • 84876344111 scopus 로고    scopus 로고
    • Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: A dose-finding study
    • Wilding JPH, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: A dose-finding study. Diabetes Obes. Metab. 2013; 15: 403-9.
    • (2013) Diabetes Obes. Metab. , vol.15 , pp. 403-409
    • Wilding, J.P.H.1    Ferrannini, E.2    Fonseca, V.A.3    Wilpshaar, W.4    Dhanjal, P.5    Houzer, A.6
  • 19
    • 84877922239 scopus 로고    scopus 로고
    • Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data
    • Kurosaki E, Ogasawara H. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data. Pharmacol. Ther. 2013; 139: 51-9.
    • (2013) Pharmacol. Ther. , vol.139 , pp. 51-59
    • Kurosaki, E.1    Ogasawara, H.2
  • 20
    • 84860492610 scopus 로고    scopus 로고
    • Discovery of ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus
    • Imamura M, Nakanishi K, Suzuki T et al. Discovery of ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg. Med. Chem. 2012; 20: 3263-79.
    • (2012) Bioorg. Med. Chem. , vol.20 , pp. 3263-3279
    • Imamura, M.1    Nakanishi, K.2    Suzuki, T.3
  • 21
    • 84866541730 scopus 로고    scopus 로고
    • Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice
    • Tahara A, Kurosaki E, Yokono M et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J. Pharmacol. Sci. 2012; 120: 36-44.
    • (2012) J. Pharmacol. Sci. , vol.120 , pp. 36-44
    • Tahara, A.1    Kurosaki, E.2    Yokono, M.3
  • 22
    • 84861544136 scopus 로고    scopus 로고
    • Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
    • Tahara A, Kurosaki E, Yokono M et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 2012; 385: 423-36.
    • (2012) Naunyn-Schmiedeberg's Arch. Pharmacol. , vol.385 , pp. 423-436
    • Tahara, A.1    Kurosaki, E.2    Yokono, M.3
  • 23
    • 84885476895 scopus 로고    scopus 로고
    • Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
    • Tahara A, Kurosaki E, Yokono M et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J. Pharmacol. 2013; 715: 246-55.
    • (2013) Eur. J. Pharmacol. , vol.715 , pp. 246-255
    • Tahara, A.1    Kurosaki, E.2    Yokono, M.3
  • 24
    • 58149295120 scopus 로고    scopus 로고
    • Nutritional regulation of glucagon-like peptide-1 secretion
    • Tolhurst G, Reimann F, Gribble FM. Nutritional regulation of glucagon-like peptide-1 secretion. J. Physiol. 2009; 587: 27-32.
    • (2009) J. Physiol. , vol.587 , pp. 27-32
    • Tolhurst, G.1    Reimann, F.2    Gribble, F.M.3
  • 25
    • 0028838030 scopus 로고
    • Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients
    • Herrmann C, Göke R, Richter G, Fehmann HC, Arnold R, Göke B. Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digestion 1995; 56: 117-26.
    • (1995) Digestion , vol.56 , pp. 117-126
    • Herrmann, C.1    Göke, R.2    Richter, G.3    Fehmann, H.C.4    Arnold, R.5    Göke, B.6
  • 26
    • 0014743725 scopus 로고
    • General survey of diabetic features of yellow KK mice
    • Iwatsuka H, Shino A, Suzuoki Z. General survey of diabetic features of yellow KK mice. Endocrinol. Jpn. 1970; 17: 23-35.
    • (1970) Endocrinol. Jpn. , vol.17 , pp. 23-35
    • Iwatsuka, H.1    Shino, A.2    Suzuoki, Z.3
  • 27
    • 0029886788 scopus 로고    scopus 로고
    • Improvement of insulin sensitivity and dyslipidemia with a new α-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects
    • Shinozaki K, Suzuki M, Ikebuchi M, Hirose J, Hara Y, Harano Y. Improvement of insulin sensitivity and dyslipidemia with a new α-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects. Metabolism 1996; 45: 731-7.
    • (1996) Metabolism , vol.45 , pp. 731-737
    • Shinozaki, K.1    Suzuki, M.2    Ikebuchi, M.3    Hirose, J.4    Hara, Y.5    Harano, Y.6
  • 28
    • 0032465376 scopus 로고    scopus 로고
    • A genetic non-insulin dependent diabetic mice KK-Ay mice, is elevated alpha-glucosyldisaccharide digestive/absorptive capacity in small intestine
    • Miura T, Ishihara E, Ishida H, Seino Y, Tanigawa K. A genetic non-insulin dependent diabetic mice KK-Ay mice, is elevated alpha-glucosyldisaccharide digestive/absorptive capacity in small intestine. Biomed. Res. 1998; 19: 335-8.
    • (1998) Biomed. Res. , vol.19 , pp. 335-338
    • Miura, T.1    Ishihara, E.2    Ishida, H.3    Seino, Y.4    Tanigawa, K.5
  • 29
    • 0026607265 scopus 로고
    • Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: Evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression
    • Hofmann CA, Edwards CW III, Hillman RM, Colca JR. Treatment of insulin-resistant mice with the oral antidiabetic agent pioglitazone: Evaluation of liver GLUT2 and phosphoenolpyruvate carboxykinase expression. Endocrinol 1992; 130: 735-40.
    • (1992) Endocrinol , vol.130 , pp. 735-740
    • Hofmann, C.A.1    Edwards III, C.W.2    Hillman, R.M.3    Colca, J.R.4
  • 30
    • 84865990718 scopus 로고    scopus 로고
    • No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects
    • Smulders RA, Zhang W, Veltkamp SA et al. No pharmacokinetic interaction between ipragliflozin and sitagliptin, pioglitazone, or glimepiride in healthy subjects. Diabetes Obes. Metab. 2012; 14: 937-43.
    • (2012) Diabetes Obes. Metab. , vol.14 , pp. 937-943
    • Smulders, R.A.1    Zhang, W.2    Veltkamp, S.A.3
  • 31
    • 84864602342 scopus 로고    scopus 로고
    • Combination treatment with ipragliflozin and metformin: A randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus
    • Veltkamp SA, van Dijk J, Collins C, van Bruijnsvoort M, Kadokura T, Smulders RA. Combination treatment with ipragliflozin and metformin: A randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus. Clin. Ther. 2012; 34: 1761-71.
    • (2012) Clin. Ther. , vol.34 , pp. 1761-1771
    • Veltkamp, S.A.1    van Dijk, J.2    Collins, C.3    van Bruijnsvoort, M.4    Kadokura, T.5    Smulders, R.A.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.